15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Cell culture and mouse studies suggest deoxycholate-mediated PGE2 inhibition or agonism of FXR could help treat colonic injury. In a mouse model of colonic mucosal biopsy injury, PGE2 levels were higher during the...
18:20 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Mouse studies suggest primary bile acids or depletion of gut microbiota could help treat liver tumors by increasing hepatic natural killer T (NKT) cell infiltration. In mouse models of liver cancer and...
13:04 , Mar 17, 2017 |  BC Week In Review  |  Company News

Retrophin restructuring news

Rare disease company Retrophin will consolidate its operations to San Diego and close its office in Cambridge, Mass., by year end. The company has about 135 employees, and will relocate select employees and hire replacements....
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Chenodeoxycholic acid regulatory update

EMA’s CHMP recommended approval of chenodeoxycholic acid from Sigma-Tau to treat cerebrotendinous xanthomatosis. The naturally occurring bile acid is approved as Xenbilox in the EU to treat gall stones. Sigma-Tau Group , Pomezia, Italy  ...
08:00 , Feb 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Farnesoid X receptor (FXR; NR1H4)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest FXR agonists could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, the endogenous FXR ligand chenodeoxycholic acid or the FXR agonist...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Clinuvel, Retrophin deal

Clinuvel rejected an unsolicited July proposal from Retrophin to acquire Clinuvel in either a cash or stock deal. The cash deal values Clinuvel at A$92.2 million ($85.6 million) and the stock deal values Clinuvel at...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Manchester Pharmaceuticals, Retrophin deal

Manchester Pharmaceuticals LLC , Fort Collins, Colo.   Retrophin Inc. (NASDAQ:RTRX), New York, N.Y.   Business: Cardiovascular, Gastrointestinal, Endocrine/Metabolic   Retrophin will acquire fellow rare disease company Manchester for $62.5 million, including $29.5 million up...
08:00 , Feb 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and...
01:23 , Feb 14, 2014 |  BC Extra  |  Company News

Retrophin jumps on Manchester deal

Retrophin Inc. (NASDAQ:RTRX) jumped $5.25 (49%) to $15.93 on Thursday after saying it will acquire fellow rare disease company Manchester Pharmaceuticals LLC (Fort Collins, Colo.) for $62.5 million, including $29.5 million up front, plus undisclosed...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Sigma-Tau S.p.A., Solvay deal

Sigma-Tau acquired Solvay's Chenix chenodeoxycholic acid tablets for an undisclosed sum. Sigma-Tau plans to develop the compound to treat cerebrotendinous xanthomatosis (CTX) disease, a metabolic disorder caused by a genetic mutation. Chenix has Orphan Drug...